Halozyme Therapeutics Inc (NASDAQ:HALO)

18.59
Delayed Data
As of 4:00pm ET
 -0.88 / -4.52%
Today’s Change
11.41
Today|||52-Week Range
21.48
-8.24%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Year
Trend

2014

2015

2016

2017
Revenue and IncomeNet Revenues75.3M135.1M146.7M316.6M
 
 
 
 
 
Cost of Goods Sold21.0M27.6M30.8M29.0M
 
 
 
 
 
Depreciation And Amortization1.8M1.7M2.4M2.2M
 
 
 
 
 
 
Operating ExpensesGross Income52.6M105.8M113.5M285.5M
 
 
 
 
 
General Expenses114.2M133.3M196.7M204.5M
 
 
 
 
 
Research And Development78.6M93.2M150.8M150.6M
 
 
 
 
 
Total Operating Expenses137.0M162.5M229.9M235.6M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-61.6M-27.5M-83.2M81.0M
 
 
 
 
 
Extraordinary Charge-1.4M0.000.000.00
 
 
Interest Expense On Debt5.6M5.2M20.0M22.0M
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-68.4M-32.2M-101.9M61.6M
 
 
 
 
 
Income Taxes0.000.00-1.2M-1.4M
 
 
 
Net Income-68.4M-32.2M-103.0M63.0M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS122.7M126.7M128.0M136.4M
 
 
 
 
 
Shares To Calculate EPS Diluted122.7M126.7M128.0M139.1M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.56-$0.25-$0.81$0.45
 
 
 
 
 
EPS Diluted-$0.56-$0.25-$0.81$0.45